Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: A sub-analysis of the CASE-J trial

Hypertension Research

Volumn 32, Issue 4, 2009, Pages 248-254

  Ogihara, Toshio ^a   Saruta, Takao ^b   Rakugi, Hiromi ^c   Fujimoto, Akira ^d   Ueshima, Kenji ^d   Yasuno, Shinji ^d   Oba, Koji ^d   Takeda, Kazuo ^e   Higaki, Jitsuo ^f   Nakao, Kazuwa ^d  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e KYOTO INDUSTRIAL HEALTH ASSOCIATION   (Japan)

^f EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CASE J; CKD; Diabetes; LVH

Indexed keywords

AMLODIPINE; CANDESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 70349695998     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2008.34     Document Type: Article

References (20)

1. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T, Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study, Diabetes 1996; 45 (Suppl 3): S14-S16, (Pubitemid 126754321)
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension, Hypertension 1992; 11: 69-76.
3. Grossman E, Messerli FH, Diabetic and hypertensive heart disease, Ann Intern Med 1996; 125: 304-310.
4. Japanese Society of Hypertension Guidelines Committee, Japanese Society of Hypertension Guideline for the Management of Hypertension (JSH2004), Hypertens Res 2006; 29: S1-105.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee\par, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report, JAMA 2003; 289: 2560-2572.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J 2007; 28: 1462-1536. (Pubitemid 46137814)
7. Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantage of angiotensin converting enzyme inhibitors in chronic renal disease, Kidney int 1996; 49 (Suppl 55): S57-S62. (Pubitemid 26000745)
8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP, Prognostic Implications of echocardiographically determined left ventricular mass in the Framingham Heart Study, W Engl J Med 1990; 322: 1561-1566. (Pubitemid 20176696)
9. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Monta S, Ogihara T, Fukiyama K, Fujishima M, Saruta T, CASE-J Study Group, Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods, Hypertens Res 2003; 26: 979-990. (Pubitemid 38128771)
10. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, for the VALUE trial group, Outcomes In hypertensive patients at high cardiovascular risk treated with regimens based in valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
11. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group, Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial, Hypertension 2008; 51: 393-398,
12. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension, Guidelines for the management of hypertension for general practitioners, Hypertension Res 2001; 24: 613-634.
13. Cockroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
14. Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality, Lancet 2000; 355: 175-180,
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762. (Pubitemid 28269185)
16. UK Prospective Diabetes Study Group, Efficacy of atenolol and captoril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39, BMJ 1998; 317: 713-720.
17. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type diabetic patients. Ann Intern Med 1993; 118: 577-581. (Pubitemid 23102690)
18. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, , AIPRD Study Group\par, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis, Ann Intern Med 2003; 139: 244-252. (Pubitemid 38129085)
19. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension, Am J Med 2003; 115:41-46. (Pubitemid 36831120)
20. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, Circulation 1997; 95: 2007-2014.